Petra Ganschow1, Lena Hofmann2, Sebastian Stintzing3,4, Volker Heinemann3, Martin Angele2, Jens Werner2, Christoph Schulz3. 1. Department of General, Visceral and Transplant Surgery, Ludwig-Maximilians University, Marchionini Str. 15, 81377, Munich, Germany. petra.ganschow@med.uni-muenchen.de. 2. Department of General, Visceral and Transplant Surgery, Ludwig-Maximilians University, Marchionini Str. 15, 81377, Munich, Germany. 3. Department of Medical Oncology, Klinikum Grosshadern and Comprehensive Cancer Center, University of Munich, Marchionini Str. 15, 81377, Munich, Germany. 4. Department of Hematology, Oncology and Tumor Immunology (CCM) Charité - Universitaetsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany.
Abstract
BACKGROUND: Perioperative treatment is the standard of care in Western Europe for locally advanced gastric cancer (GC) and adenocarcinoma of the gastroesophageal junction (GEJ). Intensified neoadjuvant treatment within the NeoFLOT trial proved to be safe and effective. Yet, the influence of such intensification with 6 cycles of FLOT in the neoadjuvant setting has not been analyzed regarding its possible impact on perioperative results. MATERIALS AND METHODS: A total of 537 patients were enrolled in this study; of whom, 132 had followed a standard neoadjuvant protocol (CTx), 356 had not received any neoadjuvant treatment (NoCTx), and 49 patients had undergone an intensified chemotherapy within the NeoFLOT trial (IntCTx) with 6 cycles ofFLOT (5-FU, leucovorin, oxaliplatin, docetaxel) every 2 weeks. RESULTS: Our results reveal no significant difference in perioperative morbidity or mortality with regard to the neoadjuvant treatment. Postoperative bleeding and hematoma occurred less frequently in the IntCTx group compared to the NoCTx and the CTx groups (2.0% vs. 5.33% vs. 5.1%). Postoperative lymph fistulas were slightly more frequent in the IntCTx group (4.1% vs. 0.3% vs. 1.6%). Patients treated within the NeoFLOT trial had a higher risk for blood transfusions (OR 5.5; 95%-KI, 2.49-12.19), whereas patients without neoadjuvant therapy had the longest ICU stay (mean 8.3 vs. CTx 4.5 vs. IntCTx 6.7 days). CONCLUSION: The results of the current study indicate that also an intensification of neoadjuvant chemotherapy with 6 preoperative cycles of FLOT does not significantly increase perioperative complications. Thus, prolonged neoadjuvant chemotherapy with FLOT is safe for patients with locally advanced GC or GEJ tumors.
RCT Entities:
BACKGROUND: Perioperative treatment is the standard of care in Western Europe for locally advanced gastric cancer (GC) and adenocarcinoma of the gastroesophageal junction (GEJ). Intensified neoadjuvant treatment within the NeoFLOT trial proved to be safe and effective. Yet, the influence of such intensification with 6 cycles of FLOT in the neoadjuvant setting has not been analyzed regarding its possible impact on perioperative results. MATERIALS AND METHODS: A total of 537 patients were enrolled in this study; of whom, 132 had followed a standard neoadjuvant protocol (CTx), 356 had not received any neoadjuvant treatment (NoCTx), and 49 patients had undergone an intensified chemotherapy within the NeoFLOT trial (IntCTx) with 6 cycles of FLOT (5-FU, leucovorin, oxaliplatin, docetaxel) every 2 weeks. RESULTS: Our results reveal no significant difference in perioperative morbidity or mortality with regard to the neoadjuvant treatment. Postoperative bleeding and hematoma occurred less frequently in the IntCTx group compared to the NoCTx and the CTx groups (2.0% vs. 5.33% vs. 5.1%). Postoperative lymph fistulas were slightly more frequent in the IntCTx group (4.1% vs. 0.3% vs. 1.6%). Patients treated within the NeoFLOT trial had a higher risk for blood transfusions (OR 5.5; 95%-KI, 2.49-12.19), whereas patients without neoadjuvant therapy had the longest ICU stay (mean 8.3 vs. CTx 4.5 vs. IntCTx 6.7 days). CONCLUSION: The results of the current study indicate that also an intensification of neoadjuvant chemotherapy with 6 preoperative cycles of FLOT does not significantly increase perioperative complications. Thus, prolonged neoadjuvant chemotherapy with FLOT is safe for patients with locally advanced GC or GEJ tumors.
Authors: Laura Lorenzon; Paolo Mercantini; Mario Ferri; Marco La Torre; Alessandra Sparagna; Genoveffa Balducci; Marco Cavallini; Vincenzo Ziparo Journal: Eur Surg Res Date: 2014-05-13 Impact factor: 1.745
Authors: Christoph Schulz; Frank Kullmann; Volker Kunzmann; Martin Fuchs; Michael Geissler; Ursula Vehling-Kaiser; Heribert Stauder; Axel Wein; Salah-Eddin Al-Batran; Thomas Kubin; Claus Schäfer; Sebastian Stintzing; Clemens Giessen; Dominik Paul Modest; Karsten Ridwelski; Volker Heinemann Journal: Int J Cancer Date: 2015-02-25 Impact factor: 7.396
Authors: K Kumagai; I Rouvelas; J A Tsai; D Mariosa; F Klevebro; M Lindblad; W Ye; L Lundell; M Nilsson Journal: Br J Surg Date: 2014-02-03 Impact factor: 6.939
Authors: Edmund K Bartlett; Robert E Roses; Rachel R Kelz; Jeffrey A Drebin; Douglas L Fraker; Giorgos C Karakousis Journal: Surgery Date: 2014-03-16 Impact factor: 3.982
Authors: David Cunningham; William H Allum; Sally P Stenning; Jeremy N Thompson; Cornelis J H Van de Velde; Marianne Nicolson; J Howard Scarffe; Fiona J Lofts; Stephen J Falk; Timothy J Iveson; David B Smith; Ruth E Langley; Monica Verma; Simon Weeden; Yu Jo Chua Journal: N Engl J Med Date: 2006-07-06 Impact factor: 91.245